^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD8 positive

    i
    Other names: CD8, CD8A, cluster of differentiation 8, CD8a Molecule, T-Cell Surface Glycoprotein CD8 Alpha Chain, T-Lymphocyte Differentiation Antigen T8/Leu-2, CD8 Antigen, Alpha Polypeptide (P32), Leu2 T-Lymphocyte Antigen, OKT8 T-Cell Antigen, T-Cell Antigen Leu2, T Cell Co-Receptor, T8 T-Cell Antigen, CD8a Antigen
    Entrez ID:
    925
    Related biomarkers:
    Expression
    Others
    Related tests:
    Apply
    BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (NCI-2019-08626) (NCT04214249)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    02/17/2021
    Primary completion :
    07/31/2024
    Completion :
    07/31/2024
    PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3
    |
    PD-L1 expression • PD-1 expression • CD8 positive • CD47 expression
    |
    Keytruda (pembrolizumab) • cytarabine • daunorubicin • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)
    Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (NCT04093323)
    Phase 2
    Roswell Park Cancer Institute
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    06/20/2024
    Primary completion :
    08/22/2025
    Completion :
    08/22/2025
    CD8
    |
    CD8 positive
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
    Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib (NCT04614194)
    Phase 2
    University of Texas Southwestern Medical Center
    Recruiting
    Last update posted :
    05/20/2024
    Initiation :
    04/15/2021
    Primary completion :
    04/15/2026
    Completion :
    04/15/2028
    HER-2 • ER • PGR • CD8
    |
    HER-2 negative • ER positive + PGR positive • PGR positive • CD8 positive
    |
    Verzenio (abemaciclib) • letrozole
    PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (CheckMate-038) (NCT01621490)
    Phase 1
    Bristol-Myers Squibb
    Completed
    Last update posted :
    04/23/2024
    Initiation :
    09/27/2012
    Primary completion :
    09/12/2017
    Completion :
    10/25/2018
    CD8 • IFNG • CXCL10 • CXCL9 • CD4
    |
    CD8 positive • CD4 positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    A Study of Ruxolitinib and Duvelisib in People With Lymphoma (NCT05010005)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    04/04/2024
    Initiation :
    08/12/2021
    Primary completion :
    08/01/2025
    Completion :
    08/01/2025
    CD8
    |
    CD8 positive
    |
    Jakafi (ruxolitinib) • Copiktra (duvelisib)
    Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer (NCT04080804)
    Phase 2
    Robert L. Ferris, MD, PhD
    Recruiting
    Last update posted :
    01/11/2024
    Initiation :
    01/08/2020
    Primary completion :
    05/31/2027
    Completion :
    09/30/2027
    TMB • LAG3
    |
    CD8 positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults (NCT03970304)
    Phase 4
    University of Maryland, Baltimore
    Active, not recruiting
    Last update posted :
    12/07/2023
    Initiation :
    10/24/2013
    Primary completion :
    06/30/2024
    Completion :
    06/30/2024
    CD8 • IFNG • TNFA
    |
    CD8 positive
    Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer (NCT05483075)
    Phase N/A
    NYU Langone Health
    Recruiting
    Last update posted :
    11/09/2023
    Initiation :
    11/15/2022
    Primary completion :
    03/01/2024
    Completion :
    09/01/2024
    CD8 • GZMB
    |
    CD8 expression • CD8 positive
    VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 (NCT03499795)
    Phase 2
    Inovio Pharmaceuticals
    Completed
    Last update posted :
    07/14/2023
    Initiation :
    05/15/2018
    Primary completion :
    06/16/2020
    Completion :
    05/26/2021
    CD8 • TNFRSF9
    |
    CD8 positive
    |
    bizalimogene ralaplasmid (VGX-3100)
    A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) (NCT02580058)
    Phase 3
    Pfizer
    Completed
    Last update posted :
    07/10/2023
    Initiation :
    12/21/2015
    Primary completion :
    09/19/2018
    Completion :
    07/12/2022
    PD-L1 • CD8
    |
    PD-L1 expression • CD8 positive
    |
    Bavencio (avelumab) • pegylated liposomal doxorubicin • doxorubicin liposomal
    WIRE - Novel Treatments in Renal Cell Cancer (NCT03741426)
    Phase 2
    CCTU- Cancer Theme
    Recruiting
    Last update posted :
    06/07/2023
    Initiation :
    07/27/2020
    Primary completion :
    11/30/2025
    Completion :
    11/30/2025
    CD8 • IL2
    |
    CD8 positive
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    Dendritic Cell Vaccination for Patients With Solid Tumors (NCT01291420)
    Phase 1/2
    University Hospital, Antwerp
    Completed
    Last update posted :
    05/12/2023
    Initiation :
    05/03/2010
    Primary completion :
    04/25/2016
    Completion :
    05/05/2018
    HER-2 • KRAS • PGR • CD8 • WT1
    |
    HER-2 negative • RAS wild-type • CD8 positive
    Metformin Treatment for Colon Cancer (MECORA) (NCT03359681)
    Phase 2
    Zealand University Hospital
    Completed
    Last update posted :
    03/03/2022
    Initiation :
    07/10/2018
    Primary completion :
    09/02/2021
    Completion :
    10/04/2021
    CD8 • CASP3
    |
    CD8 positive
    |
    metformin
    Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. (NCT05044728)
    Phase 2
    Sichuan Cancer Hospital and Research Institute
    Recruiting
    Last update posted :
    09/15/2021
    Initiation :
    04/01/2021
    Primary completion :
    04/01/2022
    Completion :
    03/31/2023
    CD8
    |
    CD8 positive
    |
    carboplatin • paclitaxel
    Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT) (NCT03453164)
    Phase 1/2
    Fukushima Medical University
    Unknown status
    Last update posted :
    07/15/2020
    Initiation :
    03/28/2018
    Primary completion :
    01/14/2021
    Completion :
    02/28/2021
    PD-L1 • CD8
    |
    PD-L1 expression • CD8 positive
    |
    Opdivo (nivolumab)
    Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer (NCT00266110)
    Phase 2
    UNC Lineberger Comprehensive Cancer Center
    Completed
    Last update posted :
    09/12/2018
    Initiation :
    12/01/2005
    Primary completion :
    02/01/2013
    Completion :
    10/27/2017
    HER-2 • CD8 • IFNG
    |
    HER-2 expression • CD8 positive
    |
    Herceptin (trastuzumab) • vinorelbine tartrate • Leukine (sargramostim)
    Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity (PRIMED-001) (NCT02993991)
    Phase 1
    University Health Network, Toronto
    Withdrawn
    Last update posted :
    12/29/2017
    Initiation :
    10/10/2017
    Primary completion :
    12/21/2017
    Completion :
    12/21/2017
    PD-L1 • CD8 • CD4
    |
    CD8 positive
    |
    Imfinzi (durvalumab) • mocetinostat (MGCD0103)
    Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery (NCT01989559)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    01/26/2015
    Initiation :
    10/01/2002
    Primary completion :
    09/01/2013
    Completion :
    09/01/2013
    CD8
    |
    CD8 positive